Genotype-Guided Tamoxifen Treatment

Policy # 00269
Original Effective Date: 09/15/2010
Current Effective Date: 11/14/2022

 Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the “Company”), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Note: Cytochrome P450 Genotype-Guided Treatment Strategy is addressed separately in medical policy 00169.

Services Are Considered Investigational
Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers genotyping to determine cytochrome p450 2D6 (CYP2D6) variants for the purpose of managing treatment with tamoxifen for individuals at high risk for or with breast cancer to be investigational.*

Background/Overview
Tamoxifen Metabolism
Tamoxifen is a pro-drug that undergoes extensive metabolism to yield its active form: 4-hydroxytamoxifen (4-OH tamoxifen) and 4-hydroxy-N-desmethyltamoxifen (endoxifen). Among these 2 metabolites, endoxifen is thought to be the major metabolite that exerts the pharmacodynamic effect of tamoxifen. The metabolism of tamoxifen into 4-OH tamoxifen is catalyzed by multiple enzymes, while endoxifen is formed predominantly by the cytochrome P450 2D6 (CYP2D6) enzyme. Plasma concentrations of endoxifen exhibit high inter-individual variability, as described in breast cancer patients. Because CYP2D6 enzyme activity is known to vary across individuals, variants in the CYP2D6 gene are of great interest for understanding tamoxifen metabolism variability and variation in levels of circulating active metabolites. Moreover, known variability in endoxifen levels has been hypothesized to result in variable responses to tamoxifen treatment.
Metabolic Enzyme Genotypes

The CYP2D6 gene exhibits a high degree of polymorphism, with more than 100 allelic variants identified. The relations among genotype, phenotype, and clinical implications are summarized in Table 1.

Table 1. Relation Among the CYP2D6 Genotype, Phenotype, and Clinical Implications

<table>
<thead>
<tr>
<th>Genotype</th>
<th>Phenotype</th>
<th>Potential Clinical Implications With Use of Tamoxifen</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥3 copies of functional alleles</td>
<td>Ultra-rapid metabolizer</td>
<td>None</td>
</tr>
<tr>
<td>Any one of the following scenarios:</td>
<td>Intermediate metabolizer</td>
<td>• Increased risk for relapse of breast cancer</td>
</tr>
<tr>
<td>1 active allele and 1 inactive allele</td>
<td></td>
<td>• Avoid concomitant use of CYP2D6 inhibitors</td>
</tr>
<tr>
<td>2 decreased activity alleles</td>
<td></td>
<td>• Consider aromatase inhibitor for postmenopausal women</td>
</tr>
<tr>
<td>1 decreased activity allele and 1 inactive allele</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 inactive alleles</td>
<td>Poor metabolizer</td>
<td>• Increased risk for relapse of breast cancer</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Consider aromatase inhibitor for postmenopausal women</td>
</tr>
</tbody>
</table>

Adapted from Swen et al (2011).

The prevalence of CYP2D6 poor metabolizers is approximately 7% to 10% in whites of Northern European descent, 1.9% to 7.3% in blacks, and 1% or less in most Asian populations studied. The poor metabolizer phenotype in whites is largely accounted for by CYP2D6*3 and *4 nonfunctional variants, and in black and Asian populations, by the *5 nonfunctional variant. Some poor metabolizers may have 1 nonfunctional allele and 1 reduced-function allele. Among reduced-function variants, CYP2D6*17, *10, and *8 are the most important in blacks, Asians, and whites, respectively. Few studies have investigated the frequency of CYP2D6-variant alleles or poor metabolizers in the Hispanic population.

Endocrine Therapy Regimens

Tamoxifen has several labeled indications:
Genotype-Guided Tamoxifen Treatment

Policy # 00269
Original Effective Date: 09/15/2010
Current Effective Date: 11/14/2022

- chemoprevention of invasive breast cancer in high-risk women without current disease or with ductal carcinoma in situ;
- adjuvant treatment of primary breast cancer; and
- treatment of metastatic disease.

In women with breast cancer, endocrine receptor-positive disease predicts a likely benefit from tamoxifen treatment. Tamoxifen is currently the most commonly prescribed adjuvant treatment to prevent recurrence of endocrine receptor-positive breast cancer in pre- or perimenopausal women.

For postmenopausal women with osteoporosis or at high risk for invasive breast cancer, raloxifene is an alternative treatment for invasive cancer risk reduction. Currently, raloxifene is indicated for the reduction in "risk of invasive breast cancer in postmenopausal women with osteoporosis" or those at "high risk for invasive breast cancer."

**Pharmacologic Inhibitors of Metabolic Enzymes**

*CYP2D6* activity may be affected not only by genotype but also by co-administered drugs that block or induce *CYP2D6* function. Studies of selective serotonin reuptake inhibitors, in particular, have shown that fluoxetine and paroxetine, but not sertraline, fluvoxamine, or venlafaxine, are potent *CYP2D6* inhibitors. Some individuals treated with fluoxetine or paroxetine have changed from an extensive metabolizer phenotype to a poor metabolizer. The degree of inhibition may depend on the selective serotonin reuptake inhibitor dose.

Thus, *CYP2D6* inhibitor use must be considered in assigning *CYP2D6* functional status, and potent *CYP2D6* inhibitors may need to be avoided when tamoxifen is administered.

**FDA or Other Governmental Regulatory Approval**

U.S. Food and Drug Administration (FDA)

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments (CLIA). *CYP2D6* genotyping assays are available under the auspices of CLIA. Laboratories that offer laboratory-developed tests must be licensed by CLIA for high-complexity testing. To date, the U.S. Food and Drug Administration (FDA) has chosen not to require any regulatory review of this test.
Several testing kits for \textit{CYP45} genotyping cleared for marketing by the FDA through the 510(k) process (FDA product code: NTI) are summarized in Table 2.

\textbf{Table 2. Testing Kits for \textit{CYP450} Genotyping Cleared for Marketing by the FDA}

<table>
<thead>
<tr>
<th>Device Name</th>
<th>Manufacturer</th>
<th>Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>xTAG CYP2D6 Kit V3</td>
<td>Luminex Molecular Diagnostics</td>
<td>2017</td>
</tr>
<tr>
<td>xTAG CYP2C19 Kit V3</td>
<td>Luminex Molecular Diagnostics</td>
<td>2013</td>
</tr>
<tr>
<td>Spartan RX CYP2C19 Test System</td>
<td>Spartan Bioscience</td>
<td>2013</td>
</tr>
<tr>
<td>xTAG CYP2D6 Kit V3 (including TDAS CYP2D6)</td>
<td>Luminex Molecular Diagnostics</td>
<td>2013</td>
</tr>
<tr>
<td>Verigene CYP2C19 Nucleic Acid Test (CYP2C19)</td>
<td>Nanosphere</td>
<td>2012</td>
</tr>
<tr>
<td>Infiniti CYP2C19 Assay</td>
<td>AutoGenomics</td>
<td>2010</td>
</tr>
<tr>
<td>xTAG CYP2D6 Kit V3, Model 1030C0300</td>
<td>Luminex Molecular Diagnostics</td>
<td>2010</td>
</tr>
<tr>
<td>Invader UGT1A1 Molecular Assay</td>
<td>Third Wave Technologies</td>
<td>2005</td>
</tr>
<tr>
<td>Roche AmpliChip CYP450 Test</td>
<td>Roche Molecular Systems</td>
<td>2005</td>
</tr>
</tbody>
</table>

FDA: U.S. Food and Drug Administration.

Several manufacturers market diagnostic genotyping panel tests for \textit{CYP450} genes, such as the YouScript Panel (Genelex Corp.), which includes \textit{CYP2D6}, \textit{CYP2C19}, \textit{CYP2C9}, \textit{VKORC1}, \textit{CYP3A4}, and \textit{CYP3A5}. Other panel tests include both \textit{CYP450} and other non-\textit{CYP450} genes involved in drug metabolism, such as the GeneSight Psychotropic panel (Assurex Health). These panel tests are beyond the scope of this medical policy.

**Rationale/Source**

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.
Genotype-Guided Tamoxifen Treatment

Policy #  00269  
Original Effective Date:  09/15/2010  
Current Effective Date:  11/14/2022

Tamoxifen is prescribed as a component of adjuvant endocrine therapy to prevent endocrine receptor-positive breast cancer recurrence, to treat metastatic breast cancer, and to prevent disease in high-risk populations and in women with ductal carcinoma in situ. Tamoxifen is a pro-drug that undergoes extensive metabolism to yield its active form: 4-hydroxytamoxifen and endoxifen (primary active form) via the cytochrome P450 2D6 (CYP2D6) enzyme. Variants in the CYP2D6 gene are associated with significant alterations in endoxifen concentrations leading to the hypothesis that CYP2D6 variation may affect the clinical outcomes of women treated with tamoxifen but not with drugs not metabolized by CYP2D6 such as anastrozole.

Summary of Evidence  
For individuals who are treated with tamoxifen for breast cancer or are at high-risk for breast cancer who receive CYP2D6 genotype-guided tamoxifen treatment, the evidence includes a single randomized controlled trial (RCT), several meta-analyses and systematic reviews, multiple retrospective and prospective cohort studies, and nonconcurrent prospective studies. Relevant outcomes include overall survival (OS), disease-specific survival, medication use, and treatment-related morbidity. Published data on the association between CYP2D6 genotype and tamoxifen treatment outcomes have yielded inconsistent results. Data in most of these studies were derived from a convenience sample, which was further limited by relatively small numbers of patients and lack of comprehensive genotype data, patient data (eg, concomitant medications), and detailed clinical outcomes data. Three influential nonconcurrent prospective studies nested within large prospective, randomized, double-blind clinical trials in postmenopausal women with hormone receptor-positive early-stage breast cancer also reported contradictory results, with 2 larger studies failing to show statistically significant associations between phenotype (patients classified as poor, intermediate, or extensive metabolizers) and recurrence of breast cancer. The RCT examining genotype-directed dosing found no difference in progression-free survival between a standard dose and increased dose; however, this trial was limited by its proof of concept design. No trials of genotype-directed drug choice that compared health outcomes for patients managed with and without the test were identified. It is not known whether CYP2D6 genotype-guided tamoxifen treatment results in the selection of a treatment strategy that would reduce the rate of breast cancer recurrence, improve disease-free survival or OS, or reduce adverse events. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.
Supplemental Information
Practice Guidelines and Position Statements
Guidelines or position statements will be considered for inclusion in ‘Supplemental Information’ if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

Clinical Pharmacogenetics Implementation Consortium
In 2018, the Clinical Pharmacogenetics Implementation Consortium issued therapeutic recommendations for tamoxifen prescribing based on CYP2D6 genotype/metabolic phenotype. For the clinical endpoints of recurrence and event-free survival, the evidence was graded as moderate for the statements that CYP2D6 poor metabolizers have a higher risk of breast cancer recurrence or worse event-free survival. However, for the comparison of other metabolizer groups and other clinical endpoints, the evidence was considered weak regarding an association between CYP2D6 metabolizer groups and clinical outcomes.

National Comprehensive Cancer Network
Regarding the use of CYP2D6 genotyping before prescribing tamoxifen, the National Comprehensive Cancer Network breast cancer guidelines (v.3.-2022) state: "CYP2D6 genotype testing is not recommended for patients considering tamoxifen."

American Society of Clinical Oncology
In 2016, the guidelines published by the American Society of Clinical Oncology (ASCO) on the use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer stated the following for CYP2D6 variants to guide adjuvant endocrine therapy selection:

- "The clinician should not use CYP2D6 polymorphisms to guide adjuvant endocrine therapy selection (Type: evidence based; Evidence quality: intermediate; Strength of recommendation: moderate).
- The ability of polymorphisms in CYP2D6 to predict tamoxifen benefit has been extensively studied. The results of these pharmacogenomics studies have been controversial, with more
recent studies being negative. At this point, data do not support the use of this marker to select patients who may or may not benefit from tamoxifen therapy."

**U.S. Preventive Services Task Force Recommendations**

Not applicable.

**Medicare National Coverage**

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

**Ongoing and Unpublished Clinical Trials**

Some currently ongoing and unpublished trials that might influence this review are listed in Table 3.

**Table 3. Summary of Key Trials**

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ongoing</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT01357772</td>
<td>Randomized Placebo-controlled Phase III Trial of Low-dose Tamoxifen in Women With Breast Intraepithelial Neoplasia</td>
<td>500</td>
<td>Dec 2028</td>
</tr>
<tr>
<td><strong>Unpublished</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT03931928</td>
<td>Genotype and Phenotype Guided Supplementation of TAMoxifen Standard Therapy With ENDOXifen in Breast Cancer Patients</td>
<td>356</td>
<td>May 2021</td>
</tr>
</tbody>
</table>

NCT: national clinical trial.

**References**

Genotype-Guided Tamoxifen Treatment

Policy # 00269
Original Effective Date: 09/15/2010
Current Effective Date: 11/14/2022


©2022 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Genotype-Guided Tamoxifen Treatment

Policy #   00269
Original Effective Date:   09/15/2010
Current Effective Date:   11/14/2022

Genotype-Guided Tamoxifen Treatment

Policy # 00269
Original Effective Date: 09/15/2010
Current Effective Date: 11/14/2022


©2022 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Genotype-Guided Tamoxifen Treatment

Policy # 00269  
Original Effective Date: 09/15/2010  
Current Effective Date: 11/14/2022


Genotype-Guided Tamoxifen Treatment

Policy # 00269
Original Effective Date: 09/15/2010
Current Effective Date: 11/14/2022


Policy History
Original Effective Date: 09/15/2010
Current Effective Date: 11/14/2022
09/09/2010 Medical Policy Committee review
09/01/2011 Medical Policy Committee review
09/14/2011 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
09/06/2012 Medical Policy Committee review
09/19/2012 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
01/23/2013 Coding updated
09/05/2013 Medical Policy Committee review
09/18/2013 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
09/04/2014 Medical Policy Committee review
09/03/2015 Medical Policy Committee review
09/08/2016 Medical Policy Committee review
Genotype-Guided Tamoxifen Treatment

Policy #  00269  
Original Effective Date:  09/15/2010  
Current Effective Date:  11/14/2022

<table>
<thead>
<tr>
<th>Date</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>09/21/2016</td>
<td>Medical Policy Implementation Committee approval. Coverage eligibility unchanged.</td>
</tr>
<tr>
<td>01/01/2017</td>
<td>Coding update: Removing ICD-9 Diagnosis Codes</td>
</tr>
<tr>
<td>09/07/2017</td>
<td>Medical Policy Committee review</td>
</tr>
<tr>
<td>09/20/2017</td>
<td>Medical Policy Implementation Committee approval. Policy revised with updated</td>
</tr>
<tr>
<td></td>
<td>genetics nomenclature; coverage eligibility otherwise unchanged.</td>
</tr>
<tr>
<td>02/06/2018</td>
<td>Coding update</td>
</tr>
<tr>
<td>10/04/2018</td>
<td>Medical Policy Committee review</td>
</tr>
<tr>
<td>10/17/2018</td>
<td>Medical Policy Implementation Committee approval. Title changed from “Genetic</td>
</tr>
<tr>
<td></td>
<td>Testing for Tamoxifen Treatment” to “Genotype Guided Tamoxifen Treatment”.</td>
</tr>
<tr>
<td></td>
<td>Coverage eligibility unchanged.</td>
</tr>
<tr>
<td>10/03/2019</td>
<td>Medical Policy Committee review</td>
</tr>
<tr>
<td>10/09/2019</td>
<td>Medical Policy Implementation Committee approval. Coverage eligibility</td>
</tr>
<tr>
<td></td>
<td>unchanged.</td>
</tr>
<tr>
<td>10/01/2020</td>
<td>Medical Policy Committee review</td>
</tr>
<tr>
<td>10/07/2020</td>
<td>Medical Policy Implementation Committee approval. Coverage eligibility</td>
</tr>
<tr>
<td></td>
<td>unchanged.</td>
</tr>
<tr>
<td>10/13/2021</td>
<td>Medical Policy Committee review</td>
</tr>
<tr>
<td>10/17/2021</td>
<td>Medical Policy Implementation Committee approval. Coverage eligibility</td>
</tr>
<tr>
<td></td>
<td>unchanged.</td>
</tr>
<tr>
<td>03/02/2022</td>
<td>Coding update</td>
</tr>
<tr>
<td>10/06/2022</td>
<td>Medical Policy Committee review</td>
</tr>
<tr>
<td>10/11/2022</td>
<td>Medical Policy Implementation Committee approval. Replaced “women” with</td>
</tr>
<tr>
<td></td>
<td>“individuals” in the investigational statement. Coverage eligibility unchanged.</td>
</tr>
</tbody>
</table>

Next Scheduled Review Date:  10/2023

**Coding**

*The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®), copyright 2021 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.*
Genotype-Guided Tamoxifen Treatment

Policy #  00269
Original Effective Date:  09/15/2010
Current Effective Date:  11/14/2022

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

<table>
<thead>
<tr>
<th>Code Type</th>
<th>Code</th>
</tr>
</thead>
</table>
| CPT            | 81226  
| HCPCS          | No codes                                                             |
| ICD-10 Diagnosis | C50.011-C50.019, C50.111-C50.119, C50.211-C50.219, C50.311-C50.319  
C50.411-C50.419, C50.511-C50.519, C50.611-C50.619  
C50.811-C50.819, C50.911-C50.919 |

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:
A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and
whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or

B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:

1. Consultation with technology evaluation center(s);
2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
3. Reference to federal regulations.

‡ Indicated trademarks are the registered trademarks of their respective owners.

**NOTICE:** If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

**NOTICE:** Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.